Temat: "COVID-19 Vaccines" - OpacWWW

Skocz do pozycji: 1.

Tytuł:: COVID-19 vaccine immunogenicity and safety surrounding fourth and subsequent vaccine doses in patients with hematologic malignancies.
Autorzy:: Bhella S; Department of Medical Oncology and Hematology, Princess Margaret Cancer Centre, University of Toronto, Toronto ON, Canada. Electronic address: .
Wilkin AM; Ottawa Hospital Research Institute, Ottawa ON, Canada.
Hueniken K; Department of Medical Oncology and Hematology, Princess Margaret Cancer Centre, University of Toronto, Toronto ON, Canada.
Vijenthira A; Department of Medical Oncology and Hematology, Princess Margaret Cancer Centre, University of Toronto, Toronto ON, Canada.
Sebag M; McGill University Health Centre, Montreal, QC, Canada.
Wang P; Department of Medicine, University of Alberta, Edmonton, AB, Canada.
Hicks LK; Division of Hematology/Oncology, St. Michael's Hospital, University of Toronto, Toronto, ON, Canada.
Hay AE; Queen's University, Kingston, ON, Canada.
Assouline S; Jewish General Hospital, Montreal, QC, Canada.
Fraser G; Department of Oncology, McMaster University, Hamilton, ON, Canada.
Balitsky A; Department of Oncology, McMaster University, Hamilton, ON, Canada.
Mangel J; Division of Hematology, Department of Medicine, Schulich School of Medicine & Dentistry, London, ON, Canada.
Owen C; University of Calgary, Tom Baker Cancer Centre, Division of Hematology and Hematological Malignancies, Calgary, AB, Canada.
Reiman A; Department of Oncology, Saint John Regional Hospital, Saint John, NB, Canada.
Sehn L; BC Cancer Centre for Lymphoma Cancer, University of British Columbia, Vancouver, BC, Canada.
Sutherland H; Leukemia/Bone Marrow Transplant Program of British Columbia, Vancouver General Hospital, BC Cancer, University of British Columbia, Vancouver, BC, Canada.
Zhang T; Ottawa Hospital Research Institute, Ottawa ON, Canada.
Arnold C; Department of Biochemistry, Microbiology and Immunology, University of Ottawa, Ottawa, ON, Canada.
Leite T; Ottawa Hospital Research Institute, Ottawa ON, Canada.
McCarthy E; Department of Medical Oncology and Hematology, Princess Margaret Cancer Centre, University of Toronto, Toronto ON, Canada.
Cooper C; Ottawa Hospital Research Institute, Ottawa ON, Canada.
Langlois MA; Department of Biochemistry, Microbiology and Immunology, University of Ottawa, Ottawa, ON, Canada.
Arianne Buchan C; Ottawa Hospital Research Institute, Ottawa ON, Canada.; Pokaż więcej
Corporate Authors:: VIP Study Investigators
Źródło:: Vaccine [Vaccine] 2024 Oct 24; Vol. 42 (24), pp. 126074. Date of Electronic Publication: 2024 Jun 28.
Typ publikacji:: Journal Article
MeSH Terms:: Hematologic Neoplasms*/immunology
Hematologic Neoplasms*/therapy
COVID-19 Vaccines*/immunology
COVID-19 Vaccines*/administration & dosage
COVID-19*/prevention & control
COVID-19*/immunology
Antibodies, Viral*/blood
Antibodies, Viral*/immunology
Immunogenicity, Vaccine*
SARS-CoV-2*/immunology
Spike Glycoprotein, Coronavirus*/immunology
Humans ; Male ; Female ; Middle Aged ; Prospective Studies ; Aged ; Adult ; Canada ; Immunity, Humoral ; Vaccination/methods ; Aged, 80 and over

Czasopismo naukowe

na półce

Full Text Finder Szczegóły

Skocz do pozycji: 2.

Tytuł:: Short- and long-term outcomes of cardiac adverse events following COVID-19 immunization managed in a Canadian pediatric center.
Autorzy:: Pham-Huy A; Division of Infectious Diseases, Immunology and Allergy, CHEO, University of Ottawa, Canada.
Bowes J; CHEO Research Institute, Canada.
Russell K; Department of Epidemiology, Ottawa Public Health, Canada.
Amira A; Department of Epidemiology, Ottawa Public Health, Canada.
Lai L; Division of Cardiology, CHEO, University of Ottawa, Canada. Electronic address: .; Pokaż więcej
Źródło:: Vaccine [Vaccine] 2024 Oct 24; Vol. 42 (24), pp. 126090. Date of Electronic Publication: 2024 Jul 12.
Typ publikacji:: Journal Article
MeSH Terms:: COVID-19*/prevention & control
COVID-19*/epidemiology
COVID-19 Vaccines*/adverse effects
COVID-19 Vaccines*/administration & dosage
Humans ; Male ; Adolescent ; Child ; Retrospective Studies ; Myocarditis/etiology ; Quality of Life ; Canada/epidemiology ; SARS-CoV-2/immunology ; Vaccination/adverse effects ; Immunization/adverse effects

Czasopismo naukowe

na półce

Full Text Finder Szczegóły

Skocz do pozycji: 3.

Tytuł:: Patient-reported outcomes of adverse events after COVID-19 vaccination in Nigeria: A mixed methods study.
Autorzy:: Ogar CK; Division of Pharmacoepidemiology and Clinical Pharmacology, Utrecht Institute for Pharmaceutical Sciences, Utrecht University, Utrecht, the Netherlands.
Gilbert HN; Harvard Medical School, Department of Global Health and Social Medicine, USA.
Bloem LT; Division of Pharmacoepidemiology and Clinical Pharmacology, Utrecht Institute for Pharmaceutical Sciences, Utrecht University, Utrecht, the Netherlands.
Leopold C; Division of Pharmacoepidemiology and Clinical Pharmacology, Utrecht Institute for Pharmaceutical Sciences, Utrecht University, Utrecht, the Netherlands.
Bassi PU; Department of Internal Medicine, College of Health Sciences, University of Abuja, Abuja, Nigeria.
Katagum YM; Department of Clinical Pharmacy & Pharmacy Administration, Bauchi State University, Gadau. Nigeria.
Osakwe AI; A - Line Pharmaceutical, Nsukka, Enugu, State, Nigeria.
Opadeyi AO; Department of Clinical Pharmacology and Therapeutics, College of Medical Sciences, University of Benin/University of Benin Teaching Hospital, Benin-City, Nigeria.
Oreagba I; Department of Pharmacology, Therapeutics and Toxicology College of Medicine University of Lagos, Lagos, Nigeria.
Mbo DND; Department of Internal Medicine, Maitama District Hospital, Abuja, Nigeria.
Mantel-Teeuwisse AK; Division of Pharmacoepidemiology and Clinical Pharmacology, Utrecht Institute for Pharmaceutical Sciences, Utrecht University, Utrecht, the Netherlands.
De Bruin ML; Division of Pharmacoepidemiology and Clinical Pharmacology, Utrecht Institute for Pharmaceutical Sciences, Utrecht University, Utrecht, the Netherlands. Electronic address: .; Pokaż więcej
Źródło:: Vaccine [Vaccine] 2024 Oct 03; Vol. 42 (23), pp. 126196. Date of Electronic Publication: 2024 Aug 22.
Typ publikacji:: Journal Article
MeSH Terms:: COVID-19 Vaccines*/adverse effects
COVID-19 Vaccines*/administration & dosage
Patient Reported Outcome Measures*
Quality of Life*
COVID-19*/prevention & control
Vaccination*/adverse effects
Vaccination*/psychology
Humans ; Female ; Male ; Nigeria ; Adult ; Adolescent ; Young Adult ; Middle Aged ; SARS-CoV-2/immunology ; Surveys and Questionnaires ; Aged ; Vaccination Hesitancy/psychology ; Vaccination Hesitancy/statistics & numerical data

Czasopismo naukowe

na półce

Full Text Finder Szczegóły

Skocz do pozycji: 4.

Tytuł:: Assessing vaccinated persons' intention to take the COVID-19 boosters using a combined theoretical framework: an online survey in Egypt.
Autorzy:: El Tantawi M; Department of Pediatric Dentistry and Dental Public Health, Faculty of Dentistry, Alexandria University, Champolion, Alexandria, Egypt. .
Elwan AH; Department of Pediatric Dentistry and Dental Public Health, Faculty of Dentistry, Alexandria University, Champolion, Alexandria, Egypt.
Hassan R; Department of Endodontics, Faculty of Dentistry, The Egyptian Russian University, Badr City, Egypt.; Department of Endodontics, Faculty of Dentistry, Minia University, Minia, Egypt.
Mohamed NF; Department of Public Health, Community, Environmental and Occupational Medicine, Faculty of Medicine Port Said University, Port Said, Egypt.
Elsheikh EI; Department of Public Health, Community, Environmental and Occupational Medicine, Faculty of Medicine Port Said University, Port Said, Egypt.
Hassan HA; Department of Pharmacognosy, Faculty of Pharmacy, Sohag University, Sohag, 82524, Egypt.
Abdelwahab SF; Department of Microbiology and Immunology, Faculty of Medicine, Minia University, Minia, 61511, Egypt.; Pokaż więcej
Źródło:: Scientific reports [Sci Rep] 2024 Oct 01; Vol. 14 (1), pp. 22795. Date of Electronic Publication: 2024 Oct 01.
Typ publikacji:: Journal Article
MeSH Terms:: COVID-19 Vaccines*/administration & dosage
COVID-19 Vaccines*/immunology
COVID-19*/prevention & control
COVID-19*/epidemiology
Intention*
Humans ; Egypt/epidemiology ; Female ; Male ; Adult ; Surveys and Questionnaires ; Young Adult ; Immunization, Secondary ; Vaccination/psychology ; Middle Aged ; SARS-CoV-2/immunology ; Health Belief Model ; Vaccination Hesitancy/psychology ; Vaccination Hesitancy/statistics & numerical data ; Adolescent ; Health Knowledge, Attitudes, Practice

Czasopismo naukowe

na półce

Full Text Finder Szczegóły

Skocz do pozycji: 5.

Tytuł:: Elucidating allergic reaction mechanisms in response to SARS-CoV-2 mRNA vaccination in adults.
Autorzy:: Shah MM; Sean N. Parker Center for Allergy & Asthma Research, Stanford, California, USA.
Layhadi JA; Immunomodulation and Tolerance Group, Allergy and Clinical Immunology, Department of National Heart and Lung Institute, Imperial College London, London, UK.
Hourcade DE; Department of Medicine, Division of Rheumatology, Washington University School of Medicine, St. Louis, Missouri, USA.
Fulton WT; Immunomodulation and Tolerance Group, Allergy and Clinical Immunology, Department of National Heart and Lung Institute, Imperial College London, London, UK.
Tan TJ; Immunomodulation and Tolerance Group, Allergy and Clinical Immunology, Department of National Heart and Lung Institute, Imperial College London, London, UK.
Dunham D; Sean N. Parker Center for Allergy & Asthma Research, Stanford, California, USA.
Chang I; Sean N. Parker Center for Allergy & Asthma Research, Stanford, California, USA.
Vel MS; Sean N. Parker Center for Allergy & Asthma Research, Stanford, California, USA.
Fernandes A; Sean N. Parker Center for Allergy & Asthma Research, Stanford, California, USA.
Lee AS; Sean N. Parker Center for Allergy & Asthma Research, Stanford, California, USA.
Liu J; Stanford Health Library, Stanford, California, USA.
Arunachalam PS; Institute for Immunity, Transplantation and Infection, Stanford University, Stanford, California, USA.
Galli SJ; Sean N. Parker Center for Allergy & Asthma Research, Stanford, California, USA.; Department of Pathology, Stanford University School of Medicine, Stanford, California, USA.; Department of Microbiology and Immunology, Stanford University School of Medicine, Stanford, California, USA.
Boyd SD; Sean N. Parker Center for Allergy & Asthma Research, Stanford, California, USA.; Department of Pathology, Stanford University School of Medicine, Stanford, California, USA.
Pulendran B; Institute for Immunity, Transplantation and Infection, Stanford University, Stanford, California, USA.; Department of Pathology, Stanford University School of Medicine, Stanford, California, USA.; Department of Microbiology and Immunology, Stanford University School of Medicine, Stanford, California, USA.
Davis MM; Institute for Immunity, Transplantation and Infection, Stanford University, Stanford, California, USA.; Department of Microbiology and Immunology, Stanford University School of Medicine, Stanford, California, USA.
O'Hara R; Department of Veteran's Administration and Dean's Office, Stanford University, Stanford, California, USA.
Park H; Veterans Affairs Palo Alto Health Care System, Palo Alto, California, USA.
Mitchell LM; Department of Medicine, Division of Rheumatology, Washington University School of Medicine, St. Louis, Missouri, USA.
Akk A; Department of Medicine, Division of Rheumatology, Washington University School of Medicine, St. Louis, Missouri, USA.
Patterson A; Department of Medicine, Division of Allergy and Immunology, Washington University School of Medicine, St. Louis, Missouri, USA.
Jerath MR; Department of Medicine, Division of Allergy and Immunology, Washington University School of Medicine, St. Louis, Missouri, USA.
Monroy JM; Department of Medicine, Division of Allergy and Immunology, Washington University School of Medicine, St. Louis, Missouri, USA.
Ren Z; Department of Medicine, Division of Allergy and Immunology, Washington University School of Medicine, St. Louis, Missouri, USA.
Kendall PL; Department of Medicine, Division of Allergy and Immunology, Washington University School of Medicine, St. Louis, Missouri, USA.
Durham SR; Immunomodulation and Tolerance Group, Allergy and Clinical Immunology, Department of National Heart and Lung Institute, Imperial College London, London, UK.
Fedina A; Immunomodulation and Tolerance Group, Allergy and Clinical Immunology, Department of National Heart and Lung Institute, Imperial College London, London, UK.
Gibbs BF; Department of Human Medicine, School of Medicine and Health Sciences, Carl von Ossietzky University of Oldenburg, Oldenburg, Germany.; Canterbury Christ Church University, Canterbury, UK.
Agache I; Faculty of Medicine, Transilvania University, Brasov, Romania.
Chinthrajah S; Sean N. Parker Center for Allergy & Asthma Research, Stanford, California, USA.
Sindher SB; Sean N. Parker Center for Allergy & Asthma Research, Stanford, California, USA.
Heider A; Swiss Institute of Allergy and Asthma Research (SIAF), University of Zurich, Davos, Switzerland.
Akdis CA; Swiss Institute of Allergy and Asthma Research (SIAF), University of Zurich, Davos, Switzerland.
Shamji MH; Immunomodulation and Tolerance Group, Allergy and Clinical Immunology, Department of National Heart and Lung Institute, Imperial College London, London, UK.
Pham CTN; Department of Medicine, Division of Rheumatology, Washington University School of Medicine, St. Louis, Missouri, USA.
Nadeau KC; Harvard T.H. Chan School of Public Health, Harvard University, Cambridge, Massachusetts, USA.; Pokaż więcej
Źródło:: Allergy [Allergy] 2024 Sep; Vol. 79 (9), pp. 2502-2523. Date of Electronic Publication: 2024 Jul 20.
Typ publikacji:: Journal Article
MeSH Terms:: COVID-19 Vaccines*/immunology
COVID-19 Vaccines*/adverse effects
COVID-19*/immunology
COVID-19*/prevention & control
SARS-CoV-2*/immunology
Basophils*/immunology
Basophils*/metabolism
Complement Activation*/immunology
Humans ; Male ; Female ; Adult ; Middle Aged ; mRNA Vaccines/immunology ; Vaccination/adverse effects ; Hypersensitivity/immunology ; Hypersensitivity/etiology ; Immunoglobulin G/immunology ; Immunoglobulin G/blood ; Aged ; Immunoglobulin E/immunology ; Immunoglobulin E/blood

Czasopismo naukowe

na półce

Full Text Finder Szczegóły

Skocz do pozycji: 6.

Tytuł:: Medical occurrence and safety of SARS-CoV-2 vaccination outside of the hospital setting.
Autorzy:: Ferrari F; Dipartimento Area Emergenza-Urgenza, Fondazione IRCCS Ca' Granda - Ospedale Maggiore Policlinico, Milan, Italy.
Sodi F; Dipartimento Area Emergenza-Urgenza, Fondazione IRCCS Ca' Granda - Ospedale Maggiore Policlinico, Milan, Italy.; Department of Pathophysiology and Transplantation, University of Milan, Padiglione Litta, Milan, Italy.
Madotto F; Dipartimento Area Emergenza-Urgenza, Fondazione IRCCS Ca' Granda - Ospedale Maggiore Policlinico, Milan, Italy.
Carlesso E; Department of Pathophysiology and Transplantation, University of Milan, Padiglione Litta, Milan, Italy.
Florio G; Dipartimento Area Emergenza-Urgenza, Fondazione IRCCS Ca' Granda - Ospedale Maggiore Policlinico, Milan, Italy.
Pelliccia MR; Department of Pathophysiology and Transplantation, University of Milan, Padiglione Litta, Milan, Italy.
Laquintana D; Direzione Aziendale Professioni Sanitarie, Fondazione IRCCS Ca' Granda - Ospedale Maggiore Policlinico, Milan, Italy.
Bisesti A; Direzione Aziendale Professioni Sanitarie, Fondazione IRCCS Ca' Granda - Ospedale Maggiore Policlinico, Milan, Italy.
Piatti A; Direzione Medica di Presidio, Fondazione IRCCS Ca' Granda - Ospedale Maggiore Policlinico, Milan, Italy.
Letzgus M; Direzione Medica di Presidio, Fondazione IRCCS Ca' Granda - Ospedale Maggiore Policlinico, Milan, Italy.
Tiwana N; Direzione Medica di Presidio, Fondazione IRCCS Ca' Granda - Ospedale Maggiore Policlinico, Milan, Italy.
Jachetti A; Emergency Department, Fondazione IRCCS Ca' Granda, Ospedale Maggiore, Milan, Italy.
Mancarella M; Emergency Department, Fondazione IRCCS Ca' Granda, Ospedale Maggiore, Milan, Italy.
Cereda D; General Directorate for Health, Lombardy Region, Milan, Italy.
Leoni O; General Directorate for Health, Lombardy Region, Milan, Italy.
Borriello CR; General Directorate for Health, Lombardy Region, Milan, Italy.
Chiappa L; Direzione Sanitaria, Fondazione IRCCS Ca' Granda - Ospedale Maggiore Policlinico, Milan, Italy.
Sottocorno M; Hospital Pharmacy Fondazione IRCCS Ca' Granda - Ospedale Maggiore Policlinico, Milan, Italy.
Costantino G; Emergency Department, Fondazione IRCCS Ca' Granda, Ospedale Maggiore, Milan, Italy.; Department of Clinical Sciences and Community Health, University of Milan, Milan, Italy.
Zanella A; Dipartimento Area Emergenza-Urgenza, Fondazione IRCCS Ca' Granda - Ospedale Maggiore Policlinico, Milan, Italy. .; Department of Pathophysiology and Transplantation, University of Milan, Padiglione Litta, Milan, Italy. .
Grasselli G; Dipartimento Area Emergenza-Urgenza, Fondazione IRCCS Ca' Granda - Ospedale Maggiore Policlinico, Milan, Italy.; Department of Pathophysiology and Transplantation, University of Milan, Padiglione Litta, Milan, Italy.; Pokaż więcej
Źródło:: Internal and emergency medicine [Intern Emerg Med] 2024 Sep; Vol. 19 (6), pp. 1593-1604. Date of Electronic Publication: 2024 Jul 23.
Typ publikacji:: Journal Article
MeSH Terms:: COVID-19 Vaccines*/adverse effects
COVID-19 Vaccines*/administration & dosage
COVID-19*/prevention & control
COVID-19*/epidemiology
Humans ; Male ; Female ; Retrospective Studies ; Middle Aged ; Adult ; Aged ; Vaccination/adverse effects ; Vaccination/statistics & numerical data ; Vaccination/methods ; Italy/epidemiology ; Adolescent ; Child ; Incidence ; SARS-CoV-2

Czasopismo naukowe

na półce

Full Text Finder Szczegóły

Skocz do pozycji: 7.

Tytuł:: COVID-19 vaccines are not associated with axonal injury in patients with multiple sclerosis.
Autorzy:: Sainz de la Maza S; Department of Neurology, Hospital Universitario Ramón y Cajal, Universidad de Alcalá, Instituto Ramón y Cajal de Investigación Sanitaria (IRYCIS), Red Española de Esclerosis Múltiple (REEM), Red de Enfermedades Inflamatorias (REI), Madrid, Spain.
Rodero-Romero A; Department of Immunology, Hospital Universitario Ramón y Cajal, Universidad de Alcalá, Instituto Ramón y Cajal de Investigación Sanitaria (IRYCIS), Red Española de Esclerosis Múltiple (REEM), Red de Enfermedades Inflamatorias (REI), Madrid, Spain.
Monreal E; Department of Neurology, Hospital Universitario Ramón y Cajal, Universidad de Alcalá, Instituto Ramón y Cajal de Investigación Sanitaria (IRYCIS), Red Española de Esclerosis Múltiple (REEM), Red de Enfermedades Inflamatorias (REI), Madrid, Spain.
Chico-García JL; Department of Neurology, Hospital Universitario Ramón y Cajal, Universidad de Alcalá, Instituto Ramón y Cajal de Investigación Sanitaria (IRYCIS), Red Española de Esclerosis Múltiple (REEM), Red de Enfermedades Inflamatorias (REI), Madrid, Spain.
Villarrubia N; Department of Immunology, Hospital Universitario Ramón y Cajal, Universidad de Alcalá, Instituto Ramón y Cajal de Investigación Sanitaria (IRYCIS), Red Española de Esclerosis Múltiple (REEM), Red de Enfermedades Inflamatorias (REI), Madrid, Spain.
Rodríguez-Jorge F; Department of Neurology, Hospital Universitario Ramón y Cajal, Universidad de Alcalá, Instituto Ramón y Cajal de Investigación Sanitaria (IRYCIS), Red Española de Esclerosis Múltiple (REEM), Red de Enfermedades Inflamatorias (REI), Madrid, Spain.
Fernández-Velasco JI; Department of Immunology, Hospital Universitario Ramón y Cajal, Universidad de Alcalá, Instituto Ramón y Cajal de Investigación Sanitaria (IRYCIS), Red Española de Esclerosis Múltiple (REEM), Red de Enfermedades Inflamatorias (REI), Madrid, Spain.
Sainz-Amo R; Department of Neurology, Hospital Universitario Ramón y Cajal, Universidad de Alcalá, Instituto Ramón y Cajal de Investigación Sanitaria (IRYCIS), Red Española de Esclerosis Múltiple (REEM), Red de Enfermedades Inflamatorias (REI), Madrid, Spain.; Department of Immunology, Hospital Universitario Ramón y Cajal, Universidad de Alcalá, Instituto Ramón y Cajal de Investigación Sanitaria (IRYCIS), Red Española de Esclerosis Múltiple (REEM), Red de Enfermedades Inflamatorias (REI), Madrid, Spain.
Costa-Frossard L; Department of Neurology, Hospital Universitario Ramón y Cajal, Universidad de Alcalá, Instituto Ramón y Cajal de Investigación Sanitaria (IRYCIS), Red Española de Esclerosis Múltiple (REEM), Red de Enfermedades Inflamatorias (REI), Madrid, Spain.
Masjuan J; Department of Neurology, Hospital Universitario Ramón y Cajal, Universidad de Alcalá, Instituto Ramón y Cajal de Investigación Sanitaria (IRYCIS), Red Española de Esclerosis Múltiple (REEM), Red de Enfermedades Inflamatorias (REI), Madrid, Spain.
Villar LM; Department of Immunology, Hospital Universitario Ramón y Cajal, Universidad de Alcalá, Instituto Ramón y Cajal de Investigación Sanitaria (IRYCIS), Red Española de Esclerosis Múltiple (REEM), Red de Enfermedades Inflamatorias (REI), Madrid, Spain.; Pokaż więcej
Źródło:: Frontiers in immunology [Front Immunol] 2024 Aug 22; Vol. 15, pp. 1439393. Date of Electronic Publication: 2024 Aug 22 (Print Publication: 2024).
Typ publikacji:: Journal Article; Observational Study
MeSH Terms:: Multiple Sclerosis*/immunology
Multiple Sclerosis*/blood
COVID-19*/immunology
COVID-19*/prevention & control
COVID-19*/blood
COVID-19 Vaccines*/adverse effects
COVID-19 Vaccines*/immunology
Neurofilament Proteins*/blood
SARS-CoV-2*/immunology
Humans ; Female ; Male ; Adult ; Middle Aged ; Young Adult ; Longitudinal Studies ; Biomarkers/blood ; Axons/pathology ; Spain/epidemiology ; Vaccination/adverse effects

Czasopismo naukowe

na półce

Full Text Finder Szczegóły

Skocz do pozycji: 8.

Tytuł:: Immunogenicity, clinical efficacy, and safety of the sinopharm (BBIBP-CorV) SARS-CoV-2 vaccine among people with multiple sclerosis receiving disease-modifying therapies: a prospective cohort study.
Autorzy:: Jameie M; Iranian Center of Neurological Research, Neuroscience Institute, Tehran University of Medical Sciences, Tehran, 1419733141, Iran.
Azizmohammad Looha M; Basic and Molecular Epidemiology of Gastrointestinal Disorders Research Center, Research Institute for Gastroenterology and Liver Diseases, Shahid Beheshti University of Medical Sciences, Tehran, Iran.
Ebadi Z; Multiple Sclerosis Research Center, Neuroscience Institute, Tehran University of Medical Sciences, Tehran, Iran.
Amanollahi M; School of Medicine, Tehran University of Medical Sciences, Tehran, Iran.
Amani K; Neurology Department, Imam Khomeini Hospital Complex, Tehran University of Medical Sciences, Tehran, Iran.
Nobahari F; School of Medicine, Tehran University of Medical Sciences, Tehran, Iran.
Abdollahi A; Department of Pathology, Imam Khomeini Hospital Complex, Tehran University of Medical Sciences, Tehran, Iran.
Mousavi M; Iranian Center of Neurological Research, Neuroscience Institute, Tehran University of Medical Sciences, Tehran, 1419733141, Iran.
Pourghaz B; Iranian Center of Neurological Research, Neuroscience Institute, Tehran University of Medical Sciences, Tehran, 1419733141, Iran.
Harirchian MH; Iranian Center of Neurological Research, Neuroscience Institute, Tehran University of Medical Sciences, Tehran, 1419733141, Iran. .; Pokaż więcej
Źródło:: BMC neurology [BMC Neurol] 2024 Aug 20; Vol. 24 (1), pp. 291. Date of Electronic Publication: 2024 Aug 20.
Typ publikacji:: Journal Article
MeSH Terms:: Antibodies, Neutralizing*/blood
Antibodies, Neutralizing*/immunology
COVID-19*/prevention & control
COVID-19*/immunology
COVID-19*/epidemiology
COVID-19 Vaccines*/adverse effects
COVID-19 Vaccines*/immunology
COVID-19 Vaccines*/administration & dosage
Multiple Sclerosis*/immunology
Multiple Sclerosis*/drug therapy
Vaccines, Inactivated*/administration & dosage
Vaccines, Inactivated*/adverse effects
Vaccines, Inactivated*/immunology
Adult ; Female ; Humans ; Male ; Middle Aged ; Antibodies, Viral/blood ; Antibodies, Viral/immunology ; Cohort Studies ; Immunogenicity, Vaccine/immunology ; Immunoglobulin G/blood ; Immunoglobulin G/immunology ; Prospective Studies ; SARS-CoV-2/immunology ; Treatment Outcome

Czasopismo naukowe

na półce

Pełny tekst Pełny tekst Szczegóły

Skocz do pozycji: 9.

Tytuł:: Lack of Evidence for Vaccine-Associated Enhanced Disease From COVID-19 Vaccines Among Adults in the Vaccine Safety Datalink.
Autorzy:: Boyce TG; Center for Clinical Epidemiology and Population Health, Marshfield Clinic Research Institute, Marshfield, Wisconsin, USA.
McClure DL; Center for Clinical Epidemiology and Population Health, Marshfield Clinic Research Institute, Marshfield, Wisconsin, USA.
Hanson KE; Center for Clinical Epidemiology and Population Health, Marshfield Clinic Research Institute, Marshfield, Wisconsin, USA.
Daley MF; Institute for Health Research, Kaiser Permanente Colorado, Aurora, Colorado, USA.
DeSilva MB; HealthPartners Institute, Bloomington, Minnesota, USA.
Irving SA; Center for Health Research, Kaiser Permanente Northwest, Portland, Oregon, USA.
Jackson LA; Kaiser Permanente Washington Health Research Institute, Seattle, Washington, USA.
Klein NP; Vaccine Study Center, Kaiser Permanente Northern California, Oakland, California, USA.
Lewin B; Department of Research and Evaluation, Kaiser Permanente Southern California, Pasadena, California, USA.
Williams JTB; Center for Health Systems Research, Denver Health & Hospital Authority, Denver, Colorado, USA.
Duffy J; Immunization Safety Office, Centers for Disease Control and Prevention, Atlanta, Georgia, USA.
McNeil MM; Immunization Safety Office, Centers for Disease Control and Prevention, Atlanta, Georgia, USA.
Weintraub ES; Immunization Safety Office, Centers for Disease Control and Prevention, Atlanta, Georgia, USA.
Belongia EA; Center for Clinical Epidemiology and Population Health, Marshfield Clinic Research Institute, Marshfield, Wisconsin, USA.; Pokaż więcej
Źródło:: Pharmacoepidemiology and drug safety [Pharmacoepidemiol Drug Saf] 2024 Aug; Vol. 33 (8), pp. e5863.
Typ publikacji:: Journal Article
MeSH Terms:: COVID-19*/prevention & control
COVID-19*/epidemiology
COVID-19 Vaccines*/adverse effects
COVID-19 Vaccines*/administration & dosage
Hospitalization*/statistics & numerical data
Severity of Illness Index*
Adult ; Aged ; Female ; Humans ; Male ; Middle Aged ; Cross-Sectional Studies ; Intensive Care Units/statistics & numerical data ; United States/epidemiology ; Vaccination/adverse effects

Czasopismo naukowe

na półce

Full Text Finder Szczegóły

Skocz do pozycji: 10.

Tytuł:: Immunogenicity of BNT162b2 as a first booster after a ChAdOx1 primary series in a Thai geriatric population living with frailty.
Autorzy:: Niyomnaitham S; Department of Pharmacology, Faculty of Medicine Siriraj Hospital, Mahidol University, Bangkok, Thailand; Siriraj Institute of Clinical Research (SICRES), Faculty of Medicine Siriraj Hospital, Mahidol University, Bangkok, 10700, Thailand. Electronic address: .
Chokephaibulkit K; Siriraj Institute of Clinical Research (SICRES), Faculty of Medicine Siriraj Hospital, Mahidol University, Bangkok, 10700, Thailand; Department of Pediatrics, Faculty of Medicine Siriraj Hospital, Mahidol University, Bangkok, 10700, Thailand. Electronic address: .
Pheerapanyawaranun C; Siriraj Institute of Clinical Research (SICRES), Faculty of Medicine Siriraj Hospital, Mahidol University, Bangkok, 10700, Thailand. Electronic address: .
Toh ZQ; Infection and Immunology, Murdoch Children's Research Institute, Parkville, Australia; Department of Pediatrics, The University of Melbourne, Parkville, Australia. Electronic address: .
Licciardi PV; Infection and Immunology, Murdoch Children's Research Institute, Parkville, Australia; Department of Pediatrics, The University of Melbourne, Parkville, Australia. Electronic address: .
Satayasanskul A; Geriatric Department, Ratchaphiphat Hospital, Bangkok, Thailand. Electronic address: .
Jansarikit L; Department of Pharmacology, Faculty of Medicine Siriraj Hospital, Mahidol University, Bangkok, Thailand. Electronic address: .
Assantachai P; Department of Preventive and Social Medicine, Faculty of Medicine Siriraj Hospital, Mahidol University, Bangkok, Thailand. Electronic address: .; Pokaż więcej
Źródło:: The journal of nutrition, health & aging [J Nutr Health Aging] 2024 Aug; Vol. 28 (8), pp. 100315. Date of Electronic Publication: 2024 Jul 17.
Typ publikacji:: Journal Article; Randomized Controlled Trial
MeSH Terms:: BNT162 Vaccine*/administration & dosage
BNT162 Vaccine*/immunology
COVID-19*/prevention & control
COVID-19*/immunology
COVID-19 Vaccines*/immunology
COVID-19 Vaccines*/administration & dosage
Immunogenicity, Vaccine*
Aged ; Aged, 80 and over ; Female ; Humans ; Male ; Antibodies, Neutralizing/blood ; Antibodies, Viral/blood ; ChAdOx1 nCoV-19 ; Frail Elderly ; Immunization, Secondary ; Injections, Intramuscular ; Prospective Studies ; Southeast Asian People ; Thailand

Czasopismo naukowe

na półce

Full Text Finder Szczegóły

Skocz do pozycji: 11.

Tytuł:: Insights from an observational translational research program during the COVID-19 pandemic: Four years of experience.
Autorzy:: Rowe M; Center for Virology and Vaccine Research, Beth Israel Deaconess Medical Center, Boston, MA, USA.
Collier AY; Center for Virology and Vaccine Research, Beth Israel Deaconess Medical Center, Boston, MA, USA; Harvard Medical School, Boston, MA, USA; Department of Obstetrics and Gynecology, Beth Israel Deaconess Medical Center, Boston, MA, USA.
Barouch DH; Center for Virology and Vaccine Research, Beth Israel Deaconess Medical Center, Boston, MA, USA; Harvard Medical School, Boston, MA, USA. Electronic address: .; Pokaż więcej
Źródło:: Vaccine [Vaccine] 2024 Oct 24; Vol. 42 (24), pp. 126306. Date of Electronic Publication: 2024 Sep 05.
Typ publikacji:: Journal Article; Observational Study
MeSH Terms:: COVID-19*/prevention & control
COVID-19*/epidemiology
COVID-19*/immunology
Translational Research, Biomedical*
SARS-CoV-2*/immunology
COVID-19 Vaccines*/immunology
COVID-19 Vaccines*/administration & dosage
Humans ; Female ; Male ; Adult ; Middle Aged ; Pregnancy ; Boston/epidemiology ; Young Adult ; Aged ; Adolescent ; Pandemics/prevention & control ; Vaccination ; Immunization, Secondary ; Child ; Aged, 80 and over

Czasopismo naukowe

na półce

Full Text Finder Szczegóły

Skocz do pozycji: 12.

Tytuł:: Jurisdiction-level costs of the initial phase of the COVID-19 vaccination program in the United States, December 20, 2020-May 31, 2021.
Autorzy:: Kim C; Epidemic Intelligence Service, Centers for Disease Control and Prevention, Atlanta, GA, USA; COVID-19 Response Team, Centers for Disease Control and Prevention, Atlanta, GA, USA. Electronic address: .
Dunphy C; COVID-19 Response Team, Centers for Disease Control and Prevention, Atlanta, GA, USA; National Center for Injury Prevention and Control, Centers for Disease Control and Prevention, Atlanta, GA, USA.
Duggar C; COVID-19 Response Team, Centers for Disease Control and Prevention, Atlanta, GA, USA.
Pike J; COVID-19 Response Team, Centers for Disease Control and Prevention, Atlanta, GA, USA; National Center for Immunization and Respiratory Diseases, Centers for Disease Control and Prevention, Atlanta, GA, USA.; Pokaż więcej
Źródło:: Vaccine [Vaccine] 2024 Oct 24; Vol. 42 (24), pp. 126287. Date of Electronic Publication: 2024 Sep 03.
Typ publikacji:: Journal Article
MeSH Terms:: COVID-19 Vaccines*/economics
COVID-19 Vaccines*/administration & dosage
COVID-19*/prevention & control
COVID-19*/economics
COVID-19*/epidemiology
Immunization Programs*/economics
Vaccination*/economics
Humans ; United States ; SARS-CoV-2/immunology

Czasopismo naukowe

na półce

Full Text Finder Szczegóły

Skocz do pozycji: 13.

Tytuł:: Risk of heavy menstrual bleeding following COVID-19 vaccination: A nationwide case-control study.
Autorzy:: Botton J; EPIPHARE Scientific Interest Group in Epidemiology of Health Products (French National Agency for the Safety of Medicines and Health Products - ANSM, French National Health Insurance - CNAM), Saint-Denis, France; Université Paris-Saclay, Faculté de pharmacie, Orsay 91400, France. Electronic address: .
Bertrand M; EPIPHARE Scientific Interest Group in Epidemiology of Health Products (French National Agency for the Safety of Medicines and Health Products - ANSM, French National Health Insurance - CNAM), Saint-Denis, France.
Jabagi MJ; EPIPHARE Scientific Interest Group in Epidemiology of Health Products (French National Agency for the Safety of Medicines and Health Products - ANSM, French National Health Insurance - CNAM), Saint-Denis, France.
Duranteau L; Department of Medical Gynecology, Bicêtre Hospital, AP.HP University Paris-Saclay, 94270 Le Kremlin Bicêtre, France.
Bouillon K; EPIPHARE Scientific Interest Group in Epidemiology of Health Products (French National Agency for the Safety of Medicines and Health Products - ANSM, French National Health Insurance - CNAM), Saint-Denis, France.
Drouin J; EPIPHARE Scientific Interest Group in Epidemiology of Health Products (French National Agency for the Safety of Medicines and Health Products - ANSM, French National Health Insurance - CNAM), Saint-Denis, France.
Semenzato L; EPIPHARE Scientific Interest Group in Epidemiology of Health Products (French National Agency for the Safety of Medicines and Health Products - ANSM, French National Health Insurance - CNAM), Saint-Denis, France.
Le Vu S; EPIPHARE Scientific Interest Group in Epidemiology of Health Products (French National Agency for the Safety of Medicines and Health Products - ANSM, French National Health Insurance - CNAM), Saint-Denis, France.
Weill A; EPIPHARE Scientific Interest Group in Epidemiology of Health Products (French National Agency for the Safety of Medicines and Health Products - ANSM, French National Health Insurance - CNAM), Saint-Denis, France.
Zureik M; EPIPHARE Scientific Interest Group in Epidemiology of Health Products (French National Agency for the Safety of Medicines and Health Products - ANSM, French National Health Insurance - CNAM), Saint-Denis, France; University Paris-Saclay, UVSQ, University Paris-Sud, Inserm, Anti-infective evasion and pharmacoepidemiology, CESP, Montigny le Bretonneux, France.
Dray-Spira R; EPIPHARE Scientific Interest Group in Epidemiology of Health Products (French National Agency for the Safety of Medicines and Health Products - ANSM, French National Health Insurance - CNAM), Saint-Denis, France.; Pokaż więcej
Źródło:: Vaccine [Vaccine] 2024 Oct 24; Vol. 42 (24), pp. 126252. Date of Electronic Publication: 2024 Sep 02.
Typ publikacji:: Journal Article
MeSH Terms:: COVID-19*/prevention & control
COVID-19*/epidemiology
COVID-19*/complications
COVID-19 Vaccines*/adverse effects
COVID-19 Vaccines*/administration & dosage
Menorrhagia*/epidemiology
Menorrhagia*/etiology
SARS-CoV-2*
Humans ; Female ; Case-Control Studies ; Adult ; Middle Aged ; France/epidemiology ; Adolescent ; Young Adult ; Vaccination/adverse effects ; Vaccination/statistics & numerical data ; Risk Factors

Czasopismo naukowe

na półce

Full Text Finder Szczegóły

Skocz do pozycji: 14.

Tytuł:: mRNA-based COVID-19 vaccination of lung transplant recipients with prior SARS-CoV-2 infection induces durable SARS-CoV-2-specific antibodies and T cells.
Autorzy:: Liu S; Department of Rheumatology and Clinical Immunology, University of Groningen, University Medical Center Groningen, the Netherlands. Electronic address: .
van Dijk LLA; Department of Viroscience, Erasmus University Medical Center, Rotterdam, the Netherlands.
den Hartog Y; Department of Internal Medicine, Nephrology and Transplantation, Erasmus MC Transplant Institute, Erasmus University Medical Center, Rotterdam, the Netherlands.
Hoek R; Department of Pulmonary Medicine, University Medical Center Rotterdam, Rotterdam, the Netherlands.
Verschuuren E; Department of Pulmonary Diseases, University Medical Center Groningen, University of Groningen, Groningen, the Netherlands.
Geurtsvankessel CH; Department of Viroscience, Erasmus University Medical Center, Rotterdam, the Netherlands.
de Vries RD; Department of Viroscience, Erasmus University Medical Center, Rotterdam, the Netherlands.
Van Baarle D; Department of Medical Microbiology, University of Groningen, University Medical Center Groningen, the Netherlands; Center for Infectious Disease Control, National Institute for Public Health and the Environment, Bilthoven, the Netherlands. Electronic address: .
Buter CVL; Department of Medical Microbiology, University of Groningen, University Medical Center Groningen, the Netherlands.; Pokaż więcej
Źródło:: Vaccine [Vaccine] 2024 Oct 24; Vol. 42 (24), pp. 126250. Date of Electronic Publication: 2024 Sep 02.
Typ publikacji:: Journal Article
MeSH Terms:: Antibodies, Viral*/blood
Antibodies, Viral*/immunology
COVID-19*/prevention & control
COVID-19*/immunology
T-Lymphocytes*/immunology
SARS-CoV-2*/immunology
Lung Transplantation*
COVID-19 Vaccines*/immunology
COVID-19 Vaccines*/administration & dosage
2019-nCoV Vaccine mRNA-1273*/immunology
Transplant Recipients*
Humans ; Middle Aged ; Male ; Female ; Adult ; Antibodies, Neutralizing/immunology ; Antibodies, Neutralizing/blood ; Spike Glycoprotein, Coronavirus/immunology ; Aged ; Vaccination ; Immunogenicity, Vaccine
SCR Organism:: SARS-CoV-2 variants

Czasopismo naukowe

na półce

Full Text Finder Szczegóły

Skocz do pozycji: 15.

Tytuł:: COVID-19 vaccine hesitancy: Meaning relations between responses in an epidemiological study and twitter messages.
Autorzy:: Ferreira-Silva SN; Faculdade Israelita de Ciências da Saúde Albert Einstein, Hospital Israelita Albert Einstein, São Paulo, SP, Brazil. Electronic address: .
Soares MEM; Faculdade Israelita de Ciências da Saúde Albert Einstein, Hospital Israelita Albert Einstein, São Paulo, SP, Brazil.
Vasconcelos R; Department of Infectious and Parasitic Diseases, Faculdade de Medicina da Universidade de São Paulo, São Paulo, SP, Brazil.
Barbieri C; Universidade Católica de Santos, Santos, SP, Brazil.
Junior LF; Baioque Conteudo, Sao Paulo, Brazil.
Medeiros T; Baioque Conteudo, Sao Paulo, Brazil.
de Souza Amorim Matos CC; Department of Preventive Medicine, Faculdade de Medicina da Universidade de São Paulo, São Paulo, SP, Brazil.
Couto MT; Department of Preventive Medicine, Faculdade de Medicina da Universidade de São Paulo, São Paulo, SP, Brazil.
Avelino-Silva VI; Faculdade Israelita de Ciências da Saúde Albert Einstein, Hospital Israelita Albert Einstein, São Paulo, SP, Brazil; Department of Infectious and Parasitic Diseases, Faculdade de Medicina da Universidade de São Paulo, São Paulo, SP, Brazil; Department of Preventive Medicine, Faculdade de Medicina da Universidade de São Paulo, São Paulo, SP, Brazil.; Pokaż więcej
Źródło:: Vaccine [Vaccine] 2024 Oct 24; Vol. 42 (24), pp. 126247. Date of Electronic Publication: 2024 Aug 27.
Typ publikacji:: Journal Article
MeSH Terms:: Social Media*
COVID-19*/prevention & control
COVID-19*/epidemiology
COVID-19 Vaccines*/administration & dosage
Vaccination Hesitancy*/psychology
Vaccination Hesitancy*/statistics & numerical data
Humans ; SARS-CoV-2 ; Vaccination/psychology ; Vaccination/statistics & numerical data ; Epidemiologic Studies ; Male ; Female ; Vaccination Refusal/psychology ; Vaccination Refusal/statistics & numerical data ; Communication ; Fear/psychology

Czasopismo naukowe

na półce

Full Text Finder Szczegóły

Skocz do pozycji: 16.

Tytuł:: Mass COVID-19 vaccination center: Optimizing the vaccination pathway during a 12 month timeframe.
Autorzy:: Le Bagousse-Bernard A; Central Pharmacy, Hospices Civils de Lyon, Lyon, France. Electronic address: .
Dussart C; Central Pharmacy, Hospices Civils de Lyon, Lyon, France.
Pin P; Resources and Purchasing Department, Hospices Civils de Lyon, Lyon, France.
Tazarourte K; Emergency Medical Service, Hospices Civils de Lyon, Lyon, France.
Fattoum J; Emergency Medical Service, Hospices Civils de Lyon, Lyon, France.; Pokaż więcej
Źródło:: Vaccine [Vaccine] 2024 Oct 24; Vol. 42 (24), pp. 126101. Date of Electronic Publication: 2024 Jul 14.
Typ publikacji:: Journal Article
MeSH Terms:: COVID-19*/prevention & control
COVID-19 Vaccines*/administration & dosage
COVID-19 Vaccines*/immunology
Mass Vaccination*/methods
Humans ; France ; Vaccination/methods ; SARS-CoV-2/immunology ; Surveys and Questionnaires ; Immunization Programs

Czasopismo naukowe

na półce

Full Text Finder Szczegóły

Skocz do pozycji: 17.

Tytuł:: Efficiency of indirect protection of COVID-19 vaccination and interactions between indirect and direct protection on household transmission.
Autorzy:: Takahashi Y; Health and Medical General Affairs Division of Osaka Prefectural Government, Japan. Electronic address: .
Tanaka H; Neyagawa City Public Health Center, 28-3 Yasakacho, Neyagawa, Osaka, Japan. Electronic address: .
Taniguchi C; College of Nursing, Aichi Medical University, 1-1 Yazakokarimata, Nagakute, Aichi, Japan. Electronic address: .
Ogata T; Itako Public Health Center of Ibaraki Prefectural Government, 1446-1 Osu, Itako, Ibaraki, Japan. Electronic address: .; Pokaż więcej
Źródło:: Vaccine [Vaccine] 2024 Oct 24; Vol. 42 (24), pp. 126110. Date of Electronic Publication: 2024 Jul 16.
Typ publikacji:: Journal Article
MeSH Terms:: COVID-19*/prevention & control
COVID-19*/transmission
COVID-19*/epidemiology
COVID-19 Vaccines*/administration & dosage
COVID-19 Vaccines*/immunology
Family Characteristics*
SARS-CoV-2*/immunology
Vaccination*/statistics & numerical data
Humans ; Female ; Male ; Adult ; Middle Aged ; Young Adult ; Adolescent ; Aged ; Child ; Child, Preschool

Czasopismo naukowe

na półce

Full Text Finder Szczegóły

Skocz do pozycji: 18.

Tytuł:: Effectiveness of COVID-19 bivalent vaccination against SARS-CoV-2 infection among residents of US nursing homes, November 2022 - March 2023.
Autorzy:: Hatfield K; Division of Healthcare Quality Promotion, National Center for Emerging and Zoonotic Infectious Diseases, Atlanta, GA, United States. Electronic address: .
Wiegand R; Coronavirus and Other Respiratory Viruses Division, National Center for Immunizations and Respiratory Diseases, Centers for Disease Control and Prevention, Atlanta, GA, United States.
Reddy S; Division of Healthcare Quality Promotion, National Center for Emerging and Zoonotic Infectious Diseases, Atlanta, GA, United States.
Patel A; Division of Healthcare Quality Promotion, National Center for Emerging and Zoonotic Infectious Diseases, Atlanta, GA, United States; Chenega Enterprise, Systems, and Solutions, Anchorage, AK, United States.
Baggs J; Division of Healthcare Quality Promotion, National Center for Emerging and Zoonotic Infectious Diseases, Atlanta, GA, United States.
Franceschini T; Signature Healthcare, Louisville, KY, United States.
Gensheimer A; Signature Healthcare, Louisville, KY, United States.
Link-Gelles R; Coronavirus and Other Respiratory Viruses Division, National Center for Immunizations and Respiratory Diseases, Centers for Disease Control and Prevention, Atlanta, GA, United States.
Jernigan J; Division of Healthcare Quality Promotion, National Center for Emerging and Zoonotic Infectious Diseases, Atlanta, GA, United States.
Wallace M; Coronavirus and Other Respiratory Viruses Division, National Center for Immunizations and Respiratory Diseases, Centers for Disease Control and Prevention, Atlanta, GA, United States.; Pokaż więcej
Źródło:: Vaccine [Vaccine] 2024 Oct 24; Vol. 42 (24), pp. 126112. Date of Electronic Publication: 2024 Jul 16.
Typ publikacji:: Journal Article
MeSH Terms:: Nursing Homes*/statistics & numerical data
COVID-19*/prevention & control
COVID-19*/epidemiology
COVID-19*/immunology
COVID-19 Vaccines*/immunology
COVID-19 Vaccines*/administration & dosage
Vaccine Efficacy*/statistics & numerical data
SARS-CoV-2*/immunology
Vaccination*/methods
Vaccination*/statistics & numerical data
Humans ; Male ; Female ; Retrospective Studies ; Aged ; Aged, 80 and over ; United States/epidemiology ; Proportional Hazards Models

Czasopismo naukowe

na półce

Full Text Finder Szczegóły

Skocz do pozycji: 19.

Tytuł:: Comparable antibody levels in heterologous and homologous mRNA COVID-19 vaccination, with superior neutralizing and IgA antibody responses in mRNA homologous boosting.
Autorzy:: Younes S; Biomedical Research Center, Qatar University, Doha, P.O. Box 2713, Qatar; Biomedical Sciences Department, College of Health Sciences, Qatar University, Doha, P.O. Box 2713, Qatar.
Nicolai E; Department of Experimental Medicine, University of Rome Tor Vergata, Via Montpellier 1, 00133 Rome, Italy.
Younes N; Biomedical Research Center, Qatar University, Doha, P.O. Box 2713, Qatar; Biomedical Sciences Department, College of Health Sciences, Qatar University, Doha, P.O. Box 2713, Qatar.
Pieri M; Department of Experimental Medicine, University of Rome Tor Vergata, Via Montpellier 1, 00133 Rome, Italy; Clinical Biochemistry, Tor Vergata University Hospital, 00133 Rome, Italy.
Bernardini S; Department of Experimental Medicine, University of Rome Tor Vergata, Via Montpellier 1, 00133 Rome, Italy; Clinical Biochemistry, Tor Vergata University Hospital, 00133 Rome, Italy.
Nizamuddin PB; Biomedical Research Center, Qatar University, Doha, P.O. Box 2713, Qatar; Biomedical Sciences Department, College of Health Sciences, Qatar University, Doha, P.O. Box 2713, Qatar.
Al-Sadeq DW; Department of Basic Medical Sciences, College of Medicine, QU Health, Qatar University, PO Box 2713, Doha, Qatar.
Daas HI; College of Dental Medicine, QU Health, Qatar University, Doha, P.O. Box 2713, Qatar.
Ismail A; Laboratory Section, Medical Commission Department, Ministry of Public Health, Doha, Qatar.
Yassine HM; Biomedical Research Center, Qatar University, Doha, P.O. Box 2713, Qatar; Biomedical Sciences Department, College of Health Sciences, Qatar University, Doha, P.O. Box 2713, Qatar.
Abu-Raddad LJ; Infectious Disease Epidemiology Group, Weill Cornell Medicine-Qatar, Cornell University, Qatar Foundation - Education City, Doha, Qatar; World Health Organization Collaborating Centre for Disease Epidemiology Analytics on HIV/AIDS, Sexually Transmitted Infections, and Viral Hepatitis, Weill Cornell Medicine-Qatar, Cornell University, Qatar Foundation, Education City, Doha, Qatar; Department of Healthcare Policy and Research, Weill Cornell Medicine, Cornell University, NY, USA.
Nasrallah GK; Biomedical Research Center, Qatar University, Doha, P.O. Box 2713, Qatar; Biomedical Sciences Department, College of Health Sciences, Qatar University, Doha, P.O. Box 2713, Qatar. Electronic address: .; Pokaż więcej
Źródło:: Vaccine [Vaccine] 2024 Oct 03; Vol. 42 (23), pp. 126042. Date of Electronic Publication: 2024 Jun 05.
Typ publikacji:: Journal Article
MeSH Terms:: Antibodies, Neutralizing*/immunology
Antibodies, Neutralizing*/blood
Immunoglobulin A*/immunology
Antibodies, Viral*/immunology
Antibodies, Viral*/blood
COVID-19*/prevention & control
COVID-19*/immunology
Immunization, Secondary*/methods
SARS-CoV-2*/immunology
SARS-CoV-2*/genetics
COVID-19 Vaccines*/immunology
COVID-19 Vaccines*/administration & dosage
Immunoglobulin G*/blood
Immunoglobulin G*/immunology
Humans ; Male ; Female ; Adult ; Middle Aged ; Young Adult ; Vaccination/methods ; Immunogenicity, Vaccine ; Spike Glycoprotein, Coronavirus/immunology ; Spike Glycoprotein, Coronavirus/genetics ; mRNA Vaccines/immunology ; 2019-nCoV Vaccine mRNA-1273/immunology ; 2019-nCoV Vaccine mRNA-1273/administration & dosage ; Aged

Czasopismo naukowe

na półce

Full Text Finder Szczegóły

Skocz do pozycji: 20.

Tytuł:: Patterns and predictors of COVID-19 vaccination among young adults at 44 US sites: Secondary analysis of a randomized, controlled, open-label trial, March - December 2021.
Autorzy:: Vielot NA; University of North Carolina at Chapel Hill, Department of Family Medicine; Chapel Hill, NC, United States. Electronic address: .
Kelly NK; University of North Carolina at Chapel Hill, Department of Epidemiology; Chapel Hill, NC, United States.
Ludema C; Indiana University Bloomington, Department of Epidemiology and Biostatistics; Bloomington, IN, United States.
Rosenberg M; Indiana University Bloomington, Department of Epidemiology and Biostatistics; Bloomington, IN, United States.
Brown ER; Vaccine and Infectious Disease Division, Fred Hutchinson Cancer Center; Seattle, WA, United States.
Janes HE; Vaccine and Infectious Disease Division, Fred Hutchinson Cancer Center; Seattle, WA, United States.
Kublin JG; Vaccine and Infectious Disease Division, Fred Hutchinson Cancer Center; Seattle, WA, United States.
Stephenson KE; Center for Virology and Vaccine Research, Beth Israel Deaconess Medical Center, Boston, MA, United States; Ragon Institute of MGH, MIT and Harvard, Cambridge, MA, United States.
Marcelin JR; Division of Infectious Diseases, University of Nebraska Medical Center, Omaha, NE, United States.
Pettifor A; University of North Carolina at Chapel Hill, Department of Epidemiology; Chapel Hill, NC, United States.; Pokaż więcej
Źródło:: Vaccine [Vaccine] 2024 Oct 03; Vol. 42 (23), pp. 126237. Date of Electronic Publication: 2024 Aug 24.
Typ publikacji:: Journal Article; Randomized Controlled Trial
MeSH Terms:: COVID-19*/prevention & control
COVID-19*/epidemiology
COVID-19 Vaccines*/administration & dosage
COVID-19 Vaccines*/immunology
Vaccination*/statistics & numerical data
SARS-CoV-2*/immunology
Humans ; Male ; Female ; Young Adult ; Adult ; United States ; Adolescent ; 2019-nCoV Vaccine mRNA-1273/immunology

Czasopismo naukowe

na półce

Full Text Finder Szczegóły

Informacja

Wyszukujesz frazę ""COVID-19 Vaccines"" wg kryterium: Temat